Last Update 22 Mar 26

Fair value Decreased 6.82%

AVAH: Refined Discount Rate And Earnings Visibility May Support Repricing Potential

Aveanna Healthcare Holdings' analyst price target has been adjusted from $11.00 to $10.25, as analysts factor in more conservative assumptions on growth and margins, while also reflecting recent upgrades and mixed target changes across several firms.

Analyst Commentary

Recent Street research on Aveanna Healthcare Holdings reflects a mix of optimism and caution, with several firms adjusting price targets in both directions and at least one upgrade alongside multiple target reductions. The new average target of $10.25 sits within this range of revised estimates.

Bullish Takeaways

Bullish analysts see enough progress on execution to justify an upgrade, even as some peers trim targets. This suggests they view recent developments as supportive of Aveanna’s business model and growth ambitions.
Multiple firms raising price targets, including increases of $0.50, $1.00 and $2.00, point to a view that Aveanna’s earnings power and cash flow potential may be better than previously reflected in their valuation work.
The upward target revisions indicate confidence that Aveanna can work within current margin assumptions. Some analysts are willing to assign higher multiples to reflect improved comfort with the company’s operating trajectory.
Supportive research commentary implies that bullish analysts see room for Aveanna to close the gap between its current share price and their revised targets, if management executes consistently on its plan.

Bearish Takeaways

Bearish analysts lowering price targets by around $1.00 highlight a more cautious stance on how quickly Aveanna can deliver on growth and margin expectations. This feeds directly into more conservative valuation frameworks.
The decision to cut targets while others are raising them shows that not all analysts are convinced current execution trends fully support higher long term assumptions on profitability or scale.
Mixed target changes across firms underline uncertainty around Aveanna’s ability to sustain its current pace of progress. Some research suggests that risk around growth, reimbursement or cost control still warrants a discount.
With the average target now at $10.25, the lower end of the target range reflects concerns that any stumble in execution could limit upside, leading cautious analysts to keep a tighter margin of safety in their models.

What's in the News

Aveanna Healthcare Holdings maintained earnings guidance for the year ending January 2, 2027, with expected revenue between US$2.54b and US$2.56b (company guidance).
For the year ending January 3, 2026, Aveanna set revenue guidance of approximately US$2.425b to US$2.445b and projected net income of approximately US$181m to US$220m (company guidance).
Alongside the 2026 outlook, Aveanna reiterated revenue expectations for the year ending January 2, 2027, in a range of US$2.54b to US$2.56b (company guidance).
For 2025, Aveanna issued updated earnings guidance with a revenue range of US$2.425b to US$2.445b, compared with prior commentary that referenced revenue of greater than US$2.375b (company guidance).

Valuation Changes

Fair Value: revised from $11.00 to $10.25, a reduction of around 7% in the modeled equity value per share.
Discount Rate: moved from 7.38% to 7.47%, a small increase that makes future cash flows slightly less valuable in the model.
Revenue Growth: adjusted from 6.73% to 5.38%, indicating more conservative assumptions for future revenue expansion.
Net Profit Margin: reduced from 5.39% to 4.13%, reflecting lower assumed profitability on each dollar of revenue.
Future P/E: lifted from 23.14x to 28.78x, implying a higher valuation multiple applied to modeled future earnings despite more cautious growth and margin inputs.

0 views

Key Takeaways

Strong demand for in-home healthcare and a growing aging population are expanding Aveanna's market opportunity and supporting sustained long-term growth.
Strategic payer relationships, efficiency initiatives, and recent acquisitions are boosting margins, cash flow, and future earnings potential.
Reliance on government funding, financial leverage, workforce challenges, and shifting healthcare delivery models threaten Aveanna's growth, margins, and long-term business sustainability.

Catalysts

About Aveanna Healthcare Holdings

A diversified home care platform company, provides pediatric and adult healthcare services in the United States.What are the underlying business or industry changes driving this perspective?

Accelerating adoption of home-based healthcare and increasing patient preference for in-home care are driving strong and sustained demand for Aveanna's services, which management repeatedly noted remains robust and outstrips the company's current capacity, supporting the potential for significant future revenue growth as the company hires and retains more caregivers.
The demographic shift toward an aging U.S. population and the rising prevalence of chronic conditions are expected to increase long-term demand for home and community-based care and skilled nursing, expanding Aveanna's total addressable market and underpinning multi-year top-line and EBITDA growth.
Successful execution of the preferred payer strategy-including a rapid increase in preferred payer agreements in all segments and legislative progress on rate enhancements-supports higher reimbursement rates, better operating leverage, and improved net margins into 2025 and beyond.
Ongoing investment in operational efficiencies (such as modernizing digital workflows, centralized billing, and preferred payer alignment) is expected to drive further margin expansion and increase free cash flow, strengthening liquidity and enabling future M&A-led growth.
Recent M&A activity, notably the Thrive Skilled Pediatric acquisition, expands Aveanna's geographic footprint, service offerings, and payer relationships, supporting both near-term adjusted EBITDA accretion and positioning the company for significant earnings growth as integration is completed and additional tuck-in acquisitions are pursued.

Aveanna Healthcare Holdings Earnings and Revenue Growth

Aveanna Healthcare Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Aveanna Healthcare Holdings's revenue will grow by 5.4% annually over the next 3 years.
Analysts assume that profit margins will shrink from 9.2% today to 4.1% in 3 years time.
Analysts expect earnings to reach $117.6 million (and earnings per share of $0.64) by about March 2029, down from $225.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 28.8x on those 2029 earnings, up from 6.3x today. This future PE is greater than the current PE for the US Healthcare industry at 21.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.47%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent wage inflation and ongoing challenges in caregiver recruitment/retention, even with targeted wage pass-throughs, could compress long-term net margins and impede revenue growth if Aveanna fails to meet increasing service demand.
Heavy dependence on Medicaid and Medicare reimbursement exposes Aveanna to significant regulatory/budgetary risks-state and federal pressures on Medicaid budgets and the proposed Medicare home health cuts (6.4% in 2026) could limit rate increases or even result in rate reductions, reducing revenue and profitability.
High leverage, with $1.47 billion in variable-rate debt, constrains financial flexibility and increases sensitivity to interest rate environments and industry downturns, posing long-term risks to earnings and raising the threat of deleveraging challenges.
Timing-related revenue and EBITDA benefits (e.g., value-based payment uplifts, one-time legal settlements) have temporarily boosted results, but normalization of these factors may reveal less robust underlying earnings growth, potentially disappointing future earnings expectations.
The ongoing shift toward technology-enabled home healthcare (telehealth, remote monitoring) among payers and patients could reduce the demand for Aveanna's traditional in-person services, challenging its core business model and impacting long-term top-line growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $10.25 for Aveanna Healthcare Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $13.0, and the most bearish reporting a price target of just $7.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.8 billion, earnings will come to $117.6 million, and it would be trading on a PE ratio of 28.8x, assuming you use a discount rate of 7.5%.
Given the current share price of $6.52, the analyst price target of $10.25 is 36.4% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Aveanna Healthcare Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Improved Earnings Visibility and Liquidity Changes Will Shape Capacity Expansion